Cited by 133Microbial Metabolic Engineering and BioproductionViral Infectious Diseases and Gene Expression in InsectsFungal and yeast genetics research

Unconventional microbial systems for the cost-efficient production of high-quality protein therapeutics

Corchero, José Luis, Gasser, Brigitte, Resina, David, Smith, Wesley, Parrilli, Ermenegilda, Vázquez, Felícitas, Abasolo, Ibane, Giuliani, Maria +7 more·2013·Biotechnology Advances

Abstract

Both conventional and innovative biomedical approaches require cost-effective protein drugs with high therapeutic potency, improved bioavailability, biocompatibility, stability and pharmacokinetics. The growing longevity of the human population, the increasing incidence and prevalence of age-related diseases and the better comprehension of genetic-linked disorders prompt to develop natural and engineered drugs addressed to fulfill emerging therapeutic demands. Conventional microbial systems have been for long time exploited to produce biotherapeutics, competing with animal cells due to easier operation and lower process costs. However, both biological platforms exhibit important drawbacks (mainly associated to intracellular retention of the product, lack of post-translational modifications and conformational stresses), that cannot be overcome through further strain optimization merely due to physiological constraints. The metabolic diversity among microorganisms offers a spectrum of unconventional hosts, that, being able to bypass some of these weaknesses, are under progressive incorporation into production pipelines. In this review we describe the main biological traits and potentials of emerging bacterial, yeast, fungal and microalgae systems, by comparing selected leading species with well established conventional organisms with a long run in protein drug production.

Integrity signals

Registry

Crossref · 10.1016/j.biotechadv.2012.09.001

Cites

259 of 259 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • There is evidence that the interplay of protein mutational robustness, protein folding and environmental stress is an additional key factor that determines the evolution of new traits.

    “Moreover, there is evidence that the interplay of protein mutational robustness, protein folding and environmental stress is an additional key factor that determines the evolution of new traits [145,146].”

Cites

Flagged first, then by citations

7 of the 266 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Authors
Corchero, J. L., Gasser, B., Resina, D., Smith, W., Parrilli, E., Vázquez, F., Abasolo, I., Giuliani, M., Jäntti, J., Ferrer, P., Saloheimo, M., Mattanovich, D., Schwartz, S., Tutino, M. L., & Villaverde, A.
Affiliations
  • Austrian Centre of Industrial Biotechnology (Austria) (AT)
  • Parc Científic de Barcelona (ES)
  • VTT Technical Research Centre of Finland (FI)
  • University of Naples Federico II (IT)
  • Universitat Autònoma de Barcelona (ES)
Corresponding author
Villaverde, Antonio
Venue
Biotechnology Advances
Publisher
Elsevier BV
Published
2013-03
Volume
31
Issue
2
Pages
140-153
ISSN
0734-9750 (ISSN-L)
OpenAlex
W2069940872
Cited by
133
References
266
Citations by year
2026: 8 · 2025: 4 · 2024: 6 · 2023: 6 · 2022: 10 · 2021: 7 · 2020: 6 · 2019: 8 · 2018: 3 · 2017: 11 · 2016: 20 · 2015: 14 · 2014: 17 · 2013: 11 · 2012: 1
FWCI
1.25
Type
journal article
Language
en
Open access
closed
Locations
  • Biotechnology Advances (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Institució Catalana de Recerca i Estudis Avançats
  • Steirische Wirtschaftsförderungsgesellschaft
  • Instituto de Salud Carlos III
  • European Regional Development Fund
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Microbial Metabolic Engineering and Bioproduction
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Viral Infectious Diseases and Gene Expression in Insects
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fungal and yeast genetics research
Keywords
therapeutic proteins, recombinant protein expression, microbial cell factories, post-translational modification, intracellular retention, recombinant yeast, recombinant bacteria
MeSH terms
Animals, Cost-Benefit Analysis, Escherichia coli, Industrial Microbiology, Mammals, Pichia, Protein Processing, Post-Translational, Recombinant Proteins, Saccharomyces cerevisiae, Trichoderma, Protein Engineering, Chlamydomonas reinhardtii, Protein Folding, Pseudoalteromonas

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review